U.S. markets close in 2 hours 9 minutes
  • S&P 500

    3,900.91
    -0.91 (-0.02%)
     
  • Dow 30

    31,576.14
    +40.63 (+0.13%)
     
  • Nasdaq

    13,509.19
    -79.64 (-0.59%)
     
  • Russell 2000

    2,250.94
    -24.38 (-1.07%)
     
  • Crude Oil

    60.65
    +0.01 (+0.02%)
     
  • Gold

    1,734.80
    +11.80 (+0.68%)
     
  • Silver

    26.93
    +0.26 (+0.96%)
     
  • EUR/USD

    1.2089
    +0.0029 (+0.24%)
     
  • 10-Yr Bond

    1.4210
    -0.0250 (-1.73%)
     
  • GBP/USD

    1.3973
    +0.0052 (+0.37%)
     
  • USD/JPY

    106.7200
    -0.0100 (-0.01%)
     
  • BTC-USD

    47,737.93
    -980.70 (-2.01%)
     
  • CMC Crypto 200

    956.22
    -30.43 (-3.08%)
     
  • FTSE 100

    6,613.75
    +25.22 (+0.38%)
     
  • Nikkei 225

    29,408.17
    -255.33 (-0.86%)
     

Surface Oncology to Present at Two Upcoming Healthcare Conferences

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- Surface Oncology (SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, announced that Jeff Goater, chief executive officer, will be participating and presenting a corporate update at the UBS Global Healthcare Conference on Wednesday, May 22, 2019 at the Grand Hyatt New York in New York City.

Additionally, Dr. Pamela Holland, PhD, vice president of cancer biology, will present at the Brisbane Immunotherapy 2019 Conference. Her presentation, “Targeting the Adenosine Axis to Treat Cancer” will take place on Friday, May 24, 2019 at the Brisbane Convention Centre, in Brisbane, Australia.

The presentations will be accessible by visiting the Investors page of the website at https://investors.surfaceoncology.com.

About Surface Oncology:

Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD73, CD39, IL-27 and CD47. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of six novel immunotherapies and a strategic collaboration with Novartis focused on NZV930 (CD73) and potentially one additional undisclosed program. For more information, please visit www.surfaceoncology.com.

Contacts:
Seth Lewis
slewis@surfaceoncology.com
617-665-5031

Krystle Gibbs
Ten Bridge Communications
krystle@tenbridgecommunications.com
508-479-6358